PVLA
The table below shows Palvella Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $42.81M | $25.90M | $31.42M | $29.32M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $22.84M | $8.15M | $8.79M | $52.98M | $66.66M | $46.53M |
| SG&A |
Palvella Therapeutics, Inc. reported annual revenue of $42.81M for fiscal year 2023. That is up 65.3% from $25.90M in fiscal 2022. Over the 10 fiscal years shown, annual revenue grew from $5.37M (FY 2014) to $42.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $15.76M |
| $5.94M |
| $3.08M |
| $16.39M |
| $16.59M |
| $16.71M |
| Operating income | -$38.60M | -$14.10M | -$11.87M | -$43.47M | -$51.83M | -$33.92M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $164.00K |
| Net income | -$41.72M | -$17.43M | $18.69M | -$33.28M | -$45.74M | -$37.23M |
| EPS (diluted) | -$3.71 | -$7.83 | $2.17 | - | -$0.71 | -$0.68 |